Micrographia Bio is a pioneering applied AI-first life
sciences company with a mission to deliver a new era
of drug discovery through spatial proteomics.

Current drug discovery methods such as genomics & transcriptomics have failed at cost-effective drug
discovery. Micrographia Bio was founded on the belief that the future of drug discovery will be driven by
spatial proteomics: the understanding of protein-protein networks inside cells that will ultimately determine
mechanisms of action of medicines.

At Micrographia Bio, we dive deep into visualising proteins in their spatial context. We are building world class
solutions to radically improve the probability of success in drug discovery. We are advancing internal pipeline
therapeutic candidates focused on fundamental cellular pathways.